Document is current

Article History

Received: 20 December 2023

Accepted: 1 February 2024

First Online: 14 March 2024

Declarations

:

: All procedures performed in this study were in accordance with local and/or national regulations and with the Declaration of Helsinki. The study protocol was approved by the institutional review board or independent ethics committee at each site.

: Written informed consent was obtained from all individual patients included in the study.

: Maxime Chénard-Poirier: Advisory board: Incyte, Merck & Co., Inc., Rahway, NJ, USA, Pfizer, and Bristol Myers Squibb. Aaron R. Hansen: Honoraria from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD), AstraZeneca, MedImmune, Pfizer, GSK, Novartis, and Bristol Myers Squibb; Consulting or advisory role for Genentech, MSD, GSK, Bristol Myers Squibb, Novartis, Boston Biomedical, and Boehringer Ingelheim; Research funding to institution from Karyopharm Therapeutics, MSD, Bristol Myers Squibb, Boehringer Ingelheim, GSK, Novartis, Genentech, and Janssen. Martin E. Gutierrez: Advisory Board: Sanofi, Incyte, Boehringer Ingelheim. Consultant: Guardant. Stock/Shares: COTA/OMI. Drew Rasco: Research funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA to support study conduct. Yan Xing: None disclosed. Lin-Chi Chen, Heng Zhou, Andrea L. Webber, Tomoko Freshwater: Employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and stockholders in Merck & Co., Inc., Rahway, NJ, USA. Manish R. Sharma: Stockholder in Merck & Co., Inc., Rahway, NJ, USA.